Skip to main content
Erschienen in: Journal of Cutaneous Medicine and Surgery 2/2004

01.04.2004 | Review

Melasma: A Review

verfasst von: Frank C. Victor, Jeremy Gelber, Babar Rao

Erschienen in: Journal of Cutaneous Medicine and Surgery | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Objective

To better understand melasma, a review of its etiologic factors, classification, pathogenesis, and treatment was undertaken.

Methods

Articles discussing the above aspects of melasma were used to demonstrate what is currently known about the disease and how to treat it.

Results

Melasma is associated with many etiologic factors, most importantly, sun exposure. It occurs in three distributions and has four reported patterns of pigmentation. Among the many differences between melasma and normal skin, melasma skin contains increased melanin, melanocytes, and melanosomes, as well as increased synthesis of tyrosinase. Its pathogenesis remains largely unknown. Treatment consists of phenolic and nonphenolic depigmenting agents, chemical peels, lasers, and dermabrasion.

Conclusion

Melasma is a common skin disorder. Although melasma has been studied, its pathogenesis remains largely unknown and its treatment is still met with difficulty. Randomized controlled trials involving larger numbers of patients and comparing treatments, as well as studying combination therapies, would be beneficial.
Literatur
1.
Zurück zum Zitat Fitzpatrick, TB, Eisen, A, Klaus, W, et al. 1987Dermatology in General Medicine3rd edMcGraw-HillNew York848849 Fitzpatrick, TB, Eisen, A, Klaus, W,  et al. 1987Dermatology in General Medicine3rd edMcGraw-HillNew York848849
2.
Zurück zum Zitat Kang, WH, Yoon, KH, Lee, E-S, et al. 2002Melasma: histopathological characteristics in 56 Korean patientsBr J Dermatol146228237CrossRefPubMed Kang, WH, Yoon, KH, Lee, E-S,  et al. 2002Melasma: histopathological characteristics in 56 Korean patientsBr J Dermatol146228237CrossRefPubMed
3.
Zurück zum Zitat Sanchez, NP, Pathak, MA, Sato, S, et al. 1981Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence studyJ Am Acad Dermatol4698710PubMed Sanchez, NP, Pathak, MA, Sato, S,  et al. 1981Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence studyJ Am Acad Dermatol4698710PubMed
4.
5.
Zurück zum Zitat Pandya, AG, Guevara, IL 2000Disorders of HyperpigmentationDermatol Clin189198PubMed Pandya, AG, Guevara, IL 2000Disorders of HyperpigmentationDermatol Clin189198PubMed
6.
Zurück zum Zitat Lufti, RJ, Fridmanis, M, Misrunas, AL, et al. 1985Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of melasmaJ Clin Endocrinol Metab612831PubMed Lufti, RJ, Fridmanis, M, Misrunas, AL,  et al. 1985Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of melasmaJ Clin Endocrinol Metab612831PubMed
7.
Zurück zum Zitat Resnick, S 1967Melasma induced by oral contraceptive drugsJAMA1999599 Resnick, S 1967Melasma induced by oral contraceptive drugsJAMA1999599
8.
Zurück zum Zitat Sturm, RA, Duffy, DL, Box, NF, et al. 2003The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypesPigment Cell Res16266272CrossRefPubMed Sturm, RA, Duffy, DL, Box, NF,  et al. 2003The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypesPigment Cell Res16266272CrossRefPubMed
9.
Zurück zum Zitat Sarangarajan, R, Boissey, RE 2001Tyrp I and oculocutaneous albinism type 3Pigment Cell Res14437444CrossRefPubMed Sarangarajan, R, Boissey, RE 2001Tyrp I and oculocutaneous albinism type 3Pigment Cell Res14437444CrossRefPubMed
10.
Zurück zum Zitat Suzuki, I, Kato, T, Motokawa, T, et al. 2002Increase of pro-opiomelanocortin mRNA prior to tyrosinase, tyrosinase-related protein 1, dopachrome tautomerase, Pmel-17/gp100, and P-protein mRNA in human skin after ultraviolet B irradiationJ Invest Dermatol1187378CrossRefPubMed Suzuki, I, Kato, T, Motokawa, T,  et al. 2002Increase of pro-opiomelanocortin mRNA prior to tyrosinase, tyrosinase-related protein 1, dopachrome tautomerase, Pmel-17/gp100, and P-protein mRNA in human skin after ultraviolet B irradiationJ Invest Dermatol1187378CrossRefPubMed
11.
Zurück zum Zitat Im, S, Moro, O, Peng, F, et al. 1998Activation of cyclic AMP pathway by alpha-melanotropin mediates the response of human melanocytes to ultraviolet B radiationCancer Res584754PubMed Im, S, Moro, O, Peng, F,  et al. 1998Activation of cyclic AMP pathway by alpha-melanotropin mediates the response of human melanocytes to ultraviolet B radiationCancer Res584754PubMed
12.
Zurück zum Zitat Im, S, Kim, J, On, W, et al. 2002Increased expression of [alpha]-melanocyte stimulating hormone in the lesional skin of melasmaBr J Dermatol146165167CrossRefPubMed Im, S, Kim, J, On, W,  et al. 2002Increased expression of [alpha]-melanocyte stimulating hormone in the lesional skin of melasmaBr J Dermatol146165167CrossRefPubMed
13.
Zurück zum Zitat Perez, M, Sanchez, JL, Aguilo, F 1983Endocrinologic profile of patients with idiopathic melasmaJ Invest Dermatol81543545PubMed Perez, M, Sanchez, JL, Aguilo, F 1983Endocrinologic profile of patients with idiopathic melasmaJ Invest Dermatol81543545PubMed
14.
Zurück zum Zitat Sialy, R, Hassan, I, Kaur, I, et al. 2000Melasma in men: a hormonal profileJ Dermatol276465PubMed Sialy, R, Hassan, I, Kaur, I,  et al. 2000Melasma in men: a hormonal profileJ Dermatol276465PubMed
15.
Zurück zum Zitat Wolf, R, Matz, H, Orion, E, et al. 2003Sunscreens—The Ultimate CosmeticActa Dermatovenerol Croat11158162PubMed Wolf, R, Matz, H, Orion, E,  et al. 2003Sunscreens—The Ultimate CosmeticActa Dermatovenerol Croat11158162PubMed
16.
Zurück zum Zitat Perez–Bernal, A, Munoz–Perez, MA, Camacho, F 2000Management of facial hyperpigmentationAm J Clin Dermatol1261268PubMed Perez–Bernal, A, Munoz–Perez, MA, Camacho, F 2000Management of facial hyperpigmentationAm J Clin Dermatol1261268PubMed
17.
Zurück zum Zitat Levin, CY, Maibach, H 2001Exogenous ochronosis. An update on clinical features, causative agents and treatment optionsAm J Clin Dermatol2213217PubMed Levin, CY, Maibach, H 2001Exogenous ochronosis. An update on clinical features, causative agents and treatment optionsAm J Clin Dermatol2213217PubMed
18.
Zurück zum Zitat Tung, RC, Bergfeld, WF, Vidimos, AT, et al. 2000alpha-Hydroxy acid-based cosmetic procedures. Guidelines for patient managementAm J Clin Dermatol18188PubMed Tung, RC, Bergfeld, WF, Vidimos, AT,  et al. 2000alpha-Hydroxy acid-based cosmetic procedures. Guidelines for patient managementAm J Clin Dermatol18188PubMed
19.
Zurück zum Zitat Lim, JT 1999Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acidDermatol Surg25282284CrossRefPubMed Lim, JT 1999Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acidDermatol Surg25282284CrossRefPubMed
20.
Zurück zum Zitat Jimbow, K 1991 N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasmaArch Dermatol12715281534CrossRefPubMed Jimbow, K 1991 N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasmaArch Dermatol12715281534CrossRefPubMed
21.
Zurück zum Zitat Fitton, A, Goa, KL 1991Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disordersDrugs41780798PubMed Fitton, A, Goa, KL 1991Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disordersDrugs41780798PubMed
22.
Zurück zum Zitat Schallreuter, KU, Wood, JW 1990A possible mechanism of action for azelaic acid in the human epidermisArch Dermatol Res282168171PubMed Schallreuter, KU, Wood, JW 1990A possible mechanism of action for azelaic acid in the human epidermisArch Dermatol Res282168171PubMed
23.
Zurück zum Zitat Nazzaro–Porro, M 1987Azelaic acidJ Am Acad Dermatol1710331041PubMed Nazzaro–Porro, M 1987Azelaic acidJ Am Acad Dermatol1710331041PubMed
24.
Zurück zum Zitat Verallo–Rowell, VM, Verallo, V, Graupe, K, et al. 1989Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasmaActa Derm Venereol Suppl (Stockh)1435861 Verallo–Rowell, VM, Verallo, V, Graupe, K,  et al. 1989Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasmaActa Derm Venereol Suppl (Stockh)1435861
25.
Zurück zum Zitat Balina, LM, Graupe, K 1991The treatment of melasma. 20% azelaic acid versus 4% hydroquinone creamInt J Dermatol30893895PubMed Balina, LM, Graupe, K 1991The treatment of melasma. 20% azelaic acid versus 4% hydroquinone creamInt J Dermatol30893895PubMed
26.
Zurück zum Zitat Yoshimura, K, Tsukamoto, K, Okazaki, M, et al. 2001Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytesJ Dermatol Sci27S6875CrossRefPubMed Yoshimura, K, Tsukamoto, K, Okazaki, M,  et al. 2001Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytesJ Dermatol Sci27S6875CrossRefPubMed
27.
Zurück zum Zitat Griffiths, CE, Finkel, LJ, Ditre, CM, et al. 1993Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trialBr J Dermatol129415421PubMed Griffiths, CE, Finkel, LJ, Ditre, CM,  et al. 1993Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trialBr J Dermatol129415421PubMed
28.
29.
Zurück zum Zitat Kligman, AM, Willis, I 1975A new formula for depigmenting human skinArch Dermatol1114048CrossRefPubMed Kligman, AM, Willis, I 1975A new formula for depigmenting human skinArch Dermatol1114048CrossRefPubMed
30.
Zurück zum Zitat Taylor, SC, Torok, H, Jones, T, et al. 2003Efficacy and safety of a new triple-combination agent for the treatment of facial melasmaCutis726772PubMed Taylor, SC, Torok, H, Jones, T,  et al. 2003Efficacy and safety of a new triple-combination agent for the treatment of facial melasmaCutis726772PubMed
31.
Zurück zum Zitat Javaheri, SM, Handa, S, Kaur, I, et al. 2001Safety and efficacy of glycolic acid facial peel in Indian women with melasmaInt J Dermatol40354357CrossRefPubMed Javaheri, SM, Handa, S, Kaur, I,  et al. 2001Safety and efficacy of glycolic acid facial peel in Indian women with melasmaInt J Dermatol40354357CrossRefPubMed
32.
Zurück zum Zitat Nouri, K, Bowes, L, Chattier, T, et al. 1999Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot studyDermatol Surg25494497CrossRefPubMed Nouri, K, Bowes, L, Chattier, T,  et al. 1999Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot studyDermatol Surg25494497CrossRefPubMed
33.
Zurück zum Zitat Kunachak, S, Leelaudomlipi, P, Wongwaisayawan, S 2001Dermabrasion: a curative treatment for melasmaAesth Plast Surg25114117CrossRef Kunachak, S, Leelaudomlipi, P, Wongwaisayawan, S 2001Dermabrasion: a curative treatment for melasmaAesth Plast Surg25114117CrossRef
Metadaten
Titel
Melasma: A Review
verfasst von
Frank C. Victor
Jeremy Gelber
Babar Rao
Publikationsdatum
01.04.2004
Erschienen in
Journal of Cutaneous Medicine and Surgery / Ausgabe 2/2004
Print ISSN: 1203-4754
Elektronische ISSN: 1615-7109
DOI
https://doi.org/10.1007/s10227-004-0158-9

Weitere Artikel der Ausgabe 2/2004

Journal of Cutaneous Medicine and Surgery 2/2004 Zur Ausgabe

Classics in Dermatology

Scabies by Kenneth Mellanby

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.